About

About
The DS management team has both a strong background in developing drugs for the market and experience in building life science companies.

Pipeline

Pipeline
DS Biopharma have three novel assets in various stages of clinical and pre-clinical development and intend to add more bioactive lipids to the current portfolio in the coming years.

Investors

Investors
To date, DS Biopharma have been funded privately.

Latest News

January 7, 2016

DS Biopharma announces positive top-line Phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis

Dublin, Ireland, January 7th, 2016 – DS Biopharma (DS), a privately held biopharmaceutical company, today announced positive top-line results from a Phase IIa clinical trial of […]
December 18, 2015

DS Biopharma announces successful completion of a Phase I safety study with bioactive lipid DS102 which is targeting NASH and IPF

Dublin, Ireland, December 18th, 2015 – DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral […]

Join our mailing list

Connect with us